The development of novel oral anticoagulants provides clinicians and patients a welcome alternative to the challenges of warfarin therapy. Dermatologists must be aware of the potential impact of novel oral anticoagulants on their surgical and medical practice. This review provides a concise summary of the novel oral anticoagulants for dermatologists with particular emphasis on: (1) the pharmacokinetic properties of these drugs and how they differ from warfarin, (2) suggested management during cutaneous surgery, (3) adverse drug interactions with commonly prescribed medications in dermatology, and (4) potential use within dermatology for treatment of disorders of cutaneous thrombosis
In today's practice, an increasing number of patients are prescribed anticoagulant therapy. Short-te...
Background: Phosphodiesterase inhibitors are commonly used drugs. Specific phosphodiesterase inhibi...
Managing patients in the perioperative setting receiving novel oral anticoagulation agents for throm...
An up-to-date overview of antithrombotic drugs, with their currently reported beneficial cutaneous e...
BACKGROUND: Bleeding is an unavoidable risk of dermatologic surgery. The risk may be higher in patie...
BACKGROUND: Bleeding is an unavoidable risk of dermatologic surgery. The risk may be higher in patie...
The oral surgeons are frequently asked to manage patients who are receiving oral anticoagulants. The...
In the past 10 years or so, many alternatives to warfarin have been developed the first being the no...
Objectives Explain the mechanisms of action, pharmacokinetics, safety concerns, monitoring paramet...
Anticoagulant drugs are among the most frequently prescribed drugs in everyday clinical practice. In...
During the past 20 years, the approval of anticoagulants such as low-molecular-weight heparins (LMWH...
Arterial and venous thromboses are major causes of mortality and morbidity. In Western countries, mo...
Historically, most patients who required parenteral anticoagulation received heparin, whereas those ...
Oral anticoagulant therapy is widely used to prevent and treat thromboembolic events. Traditionally,...
Thrombosis is an aggravation that contributes to significant morbidity and mortality rates, being a ...
In today's practice, an increasing number of patients are prescribed anticoagulant therapy. Short-te...
Background: Phosphodiesterase inhibitors are commonly used drugs. Specific phosphodiesterase inhibi...
Managing patients in the perioperative setting receiving novel oral anticoagulation agents for throm...
An up-to-date overview of antithrombotic drugs, with their currently reported beneficial cutaneous e...
BACKGROUND: Bleeding is an unavoidable risk of dermatologic surgery. The risk may be higher in patie...
BACKGROUND: Bleeding is an unavoidable risk of dermatologic surgery. The risk may be higher in patie...
The oral surgeons are frequently asked to manage patients who are receiving oral anticoagulants. The...
In the past 10 years or so, many alternatives to warfarin have been developed the first being the no...
Objectives Explain the mechanisms of action, pharmacokinetics, safety concerns, monitoring paramet...
Anticoagulant drugs are among the most frequently prescribed drugs in everyday clinical practice. In...
During the past 20 years, the approval of anticoagulants such as low-molecular-weight heparins (LMWH...
Arterial and venous thromboses are major causes of mortality and morbidity. In Western countries, mo...
Historically, most patients who required parenteral anticoagulation received heparin, whereas those ...
Oral anticoagulant therapy is widely used to prevent and treat thromboembolic events. Traditionally,...
Thrombosis is an aggravation that contributes to significant morbidity and mortality rates, being a ...
In today's practice, an increasing number of patients are prescribed anticoagulant therapy. Short-te...
Background: Phosphodiesterase inhibitors are commonly used drugs. Specific phosphodiesterase inhibi...
Managing patients in the perioperative setting receiving novel oral anticoagulation agents for throm...